IL1RL1 activates the MyD88/NF-κB signaling pathway to promote the suppressive effect of Tregs in inflammatory diseases (36), but the role of IL-33 in autoimmune diseases and tumors is controversial (36–38). The gene discussed is NFKB1; the disease is autoimmune disease.